Additionally, further investigation into the molecular mechanisms underlying GATC’s effects—particularly its modulation of the AMPK/mTOR pathway—will offer critical insights for developing targeted therapies for MASLD. Here, PRKAA2 is linked to metabolic dysfunction-associated steatotic liver disease.